γ-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells

[1]  R. Mansel,et al.  Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[2]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[3]  R. Hruban,et al.  SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.

[4]  M. Mori,et al.  Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression , 2003, Cancer.

[5]  M. Castellazzi,et al.  Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells , 2002, Oncogene.

[6]  E. Thompson,et al.  Doxycycline-Inducible Expression of SPARC/ Osteonectin/ BM40 in MDA-MB-231 Human Breast Cancer Cells Results in Growth Inhibition , 2002, Breast Cancer Research and Treatment.

[7]  H. Kanayama,et al.  Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. , 2001, The Journal of urology.

[8]  M. Yao,et al.  SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. , 2001, Human pathology.

[9]  R. Berkowitz,et al.  SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. , 2001, The American journal of pathology.

[10]  A. Nakeff,et al.  SPARC Modulates Cell Growth, Attachment and Migration of U87 Glioma Cells on Brain Extracellular Matrix Proteins , 2001, Journal of Neuro-Oncology.

[11]  J. Tonn,et al.  Targeting angiogenesis inhibits tumor infiltration and expression of the pro‐invasive protein SPARC , 2000, International journal of cancer.

[12]  R L Vessella,et al.  Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Jean-Michel,et al.  SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. , 1998, Cancer research.

[14]  D F Horrobin,et al.  Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. , 1998, Critical reviews in oncology/hematology.

[15]  J. Graham,et al.  Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. , 1997, European journal of cancer.

[16]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[17]  D. J. Plessis,et al.  The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells. , 1996 .

[18]  R. Berkowitz,et al.  SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.

[19]  R. Mansel,et al.  Regulation of the Expression of E-Cadherin on Human Cancer Cells by γ-Linolenic Acid (GLA) , 1995 .

[20]  W. Jiang,et al.  Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. , 1995, British Journal of Cancer.

[21]  P. Chambon,et al.  Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes , 1995, International journal of cancer.

[22]  M. Katayama,et al.  Osteonectin/SPARC regulates cellular secretion rates of fibronectin and laminin extracellular matrix proteins. , 1994, Biochemical and biophysical research communications.

[23]  E. Silbergeld,et al.  Lead inhibits secretion of osteonectin/SPARC without significantly altering collagen or Hsp47 production in osteoblast-like ROS 17/2.8 cells. , 1992, Toxicology and applied pharmacology.

[24]  J. Dupont.  Omega-6 Essential Fatty Acids , 1991 .

[25]  B. Hogan,et al.  Evidence for positive and negative regulatory elements in the 5'-flanking sequence of the mouse sparc (osteonectin) gene. , 1989, The Journal of biological chemistry.

[26]  D F Horrobin,et al.  Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. , 1986, Journal of the National Cancer Institute.

[27]  R. Elliott,et al.  Developmental and transformation‐sensitive expression of the Sparc gene on mouse chromosome 11. , 1986, The EMBO journal.

[28]  M. Herlyn,et al.  Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. , 2002, Cancer research.

[29]  V. Castronovo,et al.  Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.

[30]  D. Rose,et al.  Effects of linoleic acid and gamma-linolenic acid on the growth and metastasis of a human breast cancer cell line in nude mice and on its growth and invasive capacity in vitro. , 1995, Nutrition and cancer.

[31]  D. Horrobin.  Nutritional and medical importance of gamma-linolenic acid. , 1992, Progress in lipid research.

[32]  M. Tisdale,et al.  Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. , 1991, Biochemical pharmacology.

[33]  B. Hogan,et al.  Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. , 1988, Genomics.